K&L Gates Advises Rocket Pharmaceuticals on Public Offering of Common Stock
December 20, 2024
December 20, 2024
PITTSBURGH, Pennsylvania, Dec. 20 -- K&L Gates, a law firm, issued the following news release:
Global law firm K&L Gates LLP advised Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, in connection with an underwritten public offering of 15,180,000 shares of its common stock at a price to the public of US$12.50 per share. Total proceed . . .
Global law firm K&L Gates LLP advised Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, in connection with an underwritten public offering of 15,180,000 shares of its common stock at a price to the public of US$12.50 per share. Total proceed . . .